Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pravastatin in acute ischaemic syndromes: Results of a randomised placebo-controlled trial
Autore:
den Hartog, FR; van Kalmthout, PM; van Loenhout, TT; Schaafsma, HJ; Rila, H; Verheugt, FWA;
Indirizzi:
Hosp Gelderse Vallei, Dept Cardiol, NL-6710 HN Ede, Netherlands Hosp Gelderse Vallei Ede Netherlands NL-6710 HN 6710 HN Ede, Netherlands Bristol Myers Squibb Co, Woerden, Netherlands Bristol Myers Squibb Co Woerden Netherlands bb Co, Woerden, Netherlands St Radboud Acad Hosp, Dept Cardiol, Nijmegen, Netherlands St Radboud Acad Hosp Nijmegen Netherlands ardiol, Nijmegen, Netherlands
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 5, volume: 55, anno: 2001,
pagine: 300 - 304
SICI:
1368-5031(200106)55:5<300:PIAISR>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; CHOLESTEROL LEVELS; PROGRESSION; REGRESSION; MEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: den Hartog, FR Hosp Gelderse Vallei, Dept Cardiol, Willy Brandtlaan 10, NL-6710 HN Ede, Netherlands Hosp Gelderse Vallei Willy Brandtlaan 10 Ede Netherlands NL-6710 HN
Citazione:
F.R. den Hartog et al., "Pravastatin in acute ischaemic syndromes: Results of a randomised placebo-controlled trial", INT J CL PR, 55(5), 2001, pp. 300-304

Abstract

Therapy with individual 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been shown conclusively to diminish coronary event rates and mortality in both primary and secondary prevention. To date, scantattention has been paid to whether initiation of such regimens in the hospital phase of acute coronary syndromes might confer cardioprotective benefits. The purpose of this study was to determine the safety and tolerability of early initiation of statin therapy in patients with acute coronary syndromes. In this randomised, double-blind, three-month, pilot study, 100 patients with acute myocardial infarction or unstable angina and low-density lipoprotein cholesterol >3.5 mmol/l were randomly assigned to pravastatin 40 mg daily or placebo initiated within 48 hours of hospital admission. Pravastatin proved safe and well tolerated in these patients, who were well matched at baseline. No statistically significant differences in death, MI and drug-related adverse events were observed in the pravastatin group compared with control subjects. This pilot study shows that therapy with pravastatin early after an acute coronary event is safe and well tolerated. Larger, long-term studies are needed to confirm these findings.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 08:00:37